Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panobinostat - Novartis/Secura Bio

Drug Profile

Panobinostat - Novartis/Secura Bio

Alternative Names: Faridak; Farydak; LBH-589; LBH-589A

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Icahn School of Medicine at Mount Sinai; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; Secura Bio; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease; Malignant melanoma
  • Phase I Solid tumours
  • No development reported Brain metastases; CNS cancer; Diffuse intrinsic pontine glioma; Gastrointestinal stromal tumours; Glioma; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
  • Discontinued Cutaneous T-cell lymphoma; Prostate cancer

Most Recent Events

  • 14 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Diffuse intrinsic pontine glioma (In children, In adults, In adolescents, Combination therapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(Combination therapy, In children, Second-line therapy or greater, In adults) in USA (PO, Capsule)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in France (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top